MedTrace Logo

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

NCT03663569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4819

Last updated 2025-01-07

Study results available
· View outcomes & findings →

Summary

Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Spiolto® Respimat®

Drug

Sponsors & Collaborators

Principal Investigators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-15
Primary Completion
2019-10-04
Completion
2019-10-04
FDA Drug
Yes

Countries

  • Bulgaria
  • Czechia
  • Hungary
  • Israel
  • Lithuania
  • Poland
  • Romania
  • Russia
  • Slovenia
  • Switzerland
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03663569 on ClinicalTrials.gov